Vnitr Lek 2023, 69(8):534-541 | DOI: 10.36290/vnl.2023.105

What's new in nephrology?

Ivan Zahrádka, Ondřej Viklický
Klinika nefrologie, Transplantační centrum, Institut klinické a experimentální medicíny, Praha

This article summarizes the latest developments in the field of nephrology over the past year. The EMPA-KIDNEY study confirmed a significant renoprotective effect of SGLT-2 inhibitors in patients without diabetes, while a renoprotective effect in patients with diabetes was confirmed for finerenone. The STOP-ACEi study showed that discontinuation of renin-angiotensin-aldosterone system inhibitors does not confer benefit in patients with advanced chronic kidney disease. The CHAP study showed a significant beneficial effect of early treatment of hypertension above 140/90mmHg in pregnant women. It has also been confirmed that both systemic and topical corticosteroids represent viable treatment options for IgA nephropathy. Furthermore, the CONVINCE study showed that hemodiafiltration has mortality benefits over hemodialysis. The role of thiazide diuretics in the prevention of urolithiasis has been questioned by the NOSTONE study. The IgG-degrading enzyme of Streptococcus pyogenes - imlifidase - is a potentially crucial innovation for highly sensitized patients awaiting kidney transplantation. These new findings give patients hope for slowing the progression of chronic kidney disease and also improves their prospects if the need for renal replacement therapy arises.

Keywords: update, nephrology, chronic kidney disease, SGLT-2 inhibitors, hypertension, renoprotection, pregnancy, hemodialysis, hemodiafiltration, IgA nephropathy, RAS inhibition, imlifidase.

Accepted: November 27, 2023; Published: December 18, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zahrádka I, Viklický O. What's new in nephrology? Vnitr Lek. 2023;69(8):534-541. doi: 10.36290/vnl.2023.105.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Heerspink HJL, Stefánsson BV, Correa­‑Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 24. září 2020;383(15):1436-46. Go to original source... Go to PubMed...
    2. EMPA­‑KIDNEY Collaborative Group, Herrington WG, Staplin N, et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 4. listopad 2022;
    3. Baigent C, Emberson JonathanR, Haynes R, et al. Impact of diabetes on the effects of sodium glucose co­‑transporter-2 inhibitors on kidney outcomes: collaborative meta­‑analysis of large placebo­‑controlled trials. The Lancet. 19. listopad 2022;400(10365):1788-801. Go to original source... Go to PubMed...
    4. Bhandari S, Mehta S, Khwaja A, et al. Renin-Angiotensin System Inhibition in Advanced Chronic Kidney Disease. New England Journal of Medicine. 1. prosinec 2022;387(22):2021-32. Go to original source... Go to PubMed...
    5. Lv J, Zhang H, Wong MG, et al. Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. JAMA. 1. srpen 2017;318(5):432-42. Go to original source... Go to PubMed...
    6. Lv J, Wong MG, Hladunewich MA, et al. Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. JAMA. 17. květen 2022;327(19):1888-98. Go to original source... Go to PubMed...
    7. Suzuki H, Kiryluk K, Novak J, et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol. říjen 2011;22(10):1795-803. Go to original source... Go to PubMed...
    8. Barratt J, Rovin BH, Cattran D, et al. Why Target the Gut to Treat IgA Nephropathy? Kidney Int Rep. říjen 2020;5(10):1620-4. Go to original source... Go to PubMed...
    9. Welander A, Sundelin B, Fored M, et al. Increased risk of IgA nephropathy among individuals with celiac disease. J Clin Gastroenterol. září 2013;47(8):678-83. Go to original source... Go to PubMed...
    10. Smerud HK, Fellström B, Hällgren R, et al. Gluten sensitivity in patients with IgA nephropathy. Nephrol Dial Transplant. srpen 2009;24(8):2476-81. Go to original source... Go to PubMed...
    11. Kloster Smerud H, Fellström B, Hällgren R, et al. Gastrointestinal sensitivity to soy and milk proteins in patients with IgA nephropathy. Clin Nephrol. listopad 2010;74(5):364-71. Go to original source... Go to PubMed...
    12. Coppo R. The intestine­‑renal connection in IgA nephropathy. Nephrol Dial Transplant. březen 2015;30(3):360-6. Go to original source... Go to PubMed...
    13. Lafayette R, Kristensen J, Stone A, et al. Efficacy and safety of a targeted­‑release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. The Lancet [Internet]. 14. srpen 2023 [cited 26. 8. 2023];0(0). Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01554-4/fulltext
    14. Barratt J, Lafayette R, Kristensen J, et al. Results from part A of the multi­‑center, double­‑blind, randomized, placebo­‑controlled NefIgArd trial, which evaluated targeted­‑release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney International. 1. únor 2023;103(2):391-402. Go to original source... Go to PubMed...
    15. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy. Obstet Gynecol. leden 2019;133(1):e26-50. Go to original source... Go to PubMed...
    16. Garovic VD, Dechend R, Easterling T, et al. Hypertension in Pregnancy: Diagnosis, Blood Pressure Goals, and Pharmacotherapy: A Scientific Statement From the American Heart Association. Hypertension. únor 2022;79(2):e21-41. Go to original source... Go to PubMed...
    17. Sinkey RG, Battarbee AN, Bello NA, et al. Prevention, Diagnosis, and Management of Hypertensive Disorders of Pregnancy: a Comparison of International Guidelines. Curr Hypertens Rep. 27. srpen 2020;22(9):66. Go to original source... Go to PubMed...
    18. Tita AT, Szychowski JM, Boggess K, et al. Treatment for Mild Chronic Hypertension during Pregnancy. N Engl J Med. 12. květen 2022;386(19):1781-92. Go to original source... Go to PubMed...
    19. Nistor I, Palmer SC, Craig JC, et al. Haemodiafiltration, haemofiltration and haemodialysis for end­‑stage kidney disease. Cochrane Database Syst Rev. 20. květen 2015;(5):CD006258. Go to original source...
    20. Blankestijn PJ, Vernooij RWM, Hockham C, et al. Effect of Hemodiafiltration or Hemodialysis on Mortality in Kidney Failure. New England Journal of Medicine. 16. červen 2023;0(0):null. Go to original source... Go to PubMed...
    21. Národní registr dialyzovaných pacientů [Internet]. [citován 15. srpen 2023]. Dostupné z: http://www.nefro.cz/o­‑rdp/prezentace/
    22. Frassetto L, Kohlstadt I. Treatment and Prevention of Kidney Stones: An Update. afp. 1. prosinec 2011;84(11):1234-42.
    23. Alexander RT. Do Thiazides Reduce the Risk of Kidney­‑Stone Recurrence? New England Journal of Medicine. 2. březen 2023;388(9):841-2. Go to original source... Go to PubMed...
    24. Dhayat NA, Bonny O, Roth B, et al. Hydrochlorothiazide and Prevention of Kidney­‑Stone Recurrence. New England Journal of Medicine. 2. březen 2023;388(9):781-91. Go to original source... Go to PubMed...
    25. Ubaid­‑Girioli S, Ferreira­‑Melo SE, Souza LA, et al. Aldosterone Escape With Diuretic or Angiotensin­‑Converting Enzyme Inhibitor/Angiotensin II Receptor Blocker Combination Therapy in Patients With Mild to Moderate Hypertension. J Clin Hypertens (Greenwich). 2. říjen 2013;9(10):770-4. Go to original source... Go to PubMed...
    26. Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. New England Journal of Medicine. 3. prosinec 2020;383(23):2219-29. Go to original source... Go to PubMed...
    27. Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. New England Journal of Medicine. 9. prosinec 2021;385(24):2252-63. Go to original source... Go to PubMed...
    28. Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. European Heart Journal. 7. únor 2022;43(6):474-84. Go to original source... Go to PubMed...
    29. Jordan SC, Lorant T, Choi J. IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation. N Engl J Med. 26. říjen 2017;377(17):1693-4. Go to original source...
    30. Jordan SC, Legendre C, Desai NM, et al. Imlifidase Desensitization in Crossmatch­‑positive, Highly Sensitized Kidney Transplant Recipients: Results of an International Phase 2 Trial (Highdes). Transplantation. 1. srpen 2021;105(8):1808-17. Go to original source... Go to PubMed...
    31. Lonze BE, Tatapudi VS, Weldon EP, et al. IdeS (Imlifidase): A Novel Agent That Cleaves Human IgG and Permits Successful Kidney Transplantation Across High­‑strength Donor­‑specific Antibody. Ann Surg. září 2018;268(3):488-96. Go to original source... Go to PubMed...
    32. Kjellman C, Maldonado AQ, Sjöholm K, et al. Outcomes at 3 years posttransplant in imlifidase­‑desensitized kidney transplant patients. Am J Transplant. prosinec 2021;21(12):3907-18. Go to original source... Go to PubMed...
    33. Uhlin F, Szpirt W, Kronbichler A, et al. Endopeptidase Cleavage of Anti­‑Glomerular Basement Membrane Antibodies in vivo in Severe Kidney Disease: An Open­‑Label Phase 2a Study. J Am Soc Nephrol. duben 2022;33(4):829-38. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.